Stopping Denosumab: What the Rebound-Fracture Evidence Shows About Discontinuation

Stopping denosumab is not like finishing a course of most other bone medicines, because its protection ends the moment the drug clears rather than tapering off. When a dose is missed and no follow-on treatment takes its place, bone turnover rebounds above where it began, and post hoc analyses of the FREEDOM trial and its Extension tie that rebound to a sharp, clustered rise in spinal fractures. That is the reason osteoporosis societies now frame discontinuation as a decision that needs a plan, and it has nothing to do with how well the drug works while you are taking it.

Key points#

• Denosumab does not stay bound in bone, so its effect is fully reversible and ends soon after a missed dose.
• After stopping, bone turnover markers climb past baseline and the density gained on treatment is largely lost within about one to two years.
• In FREEDOM Extension analyses, new vertebral fracture rates rose several-fold after discontinuation, and most people who fractured had more than one.
• The high-risk window is front-loaded, roughly eight to sixteen months after the last injection.
• Guidelines advise transitioning to another antiresorptive rather than simply stopping.

The pattern the trial data revealed#

The most cited evidence is a post hoc analysis by Cummings and colleagues in the Journal of Bone and Mineral Research (2018), drawn from the randomized placebo-controlled FREEDOM trial and its long-term Extension. Among participants who came off denosumab, the rate of new vertebral fractures climbed from roughly 1.2 per 100 participant-years during treatment to about 7.1 per 100 participant-years after stopping. In effect, the off-treatment fracture rate returned toward what the placebo group experienced, but compressed into the months right after the last dose rather than spread across years.

The detail that drew the most concern was not the overall rise but its shape. The rate of multiple vertebral fractures jumped from about 0.4 to 4.2 per 100 participant-years, and of those who fractured after stopping, roughly 61 percent had two or more vertebral fractures at once. Prior vertebral fracture, whether before treatment or during the off-treatment stretch, marked people at higher risk. Because this analysis was not designed to test discontinuation and the number of events was small, the precise figures deserve caution. The direction and the clustering, however, have held up across the trial data and later case series firmly enough to guide practice.

A 2018 report in CMAJ carried the finding into wider clinical view, describing a roughly sixfold rise in vertebral fracture rate after cessation and the tendency for several fractures to strike the same person. A 2023 review in the Journal of Clinical Medicine later placed the usual timing of these rebound-associated fractures at about eight to sixteen months after the final injection, often announcing themselves as sudden, severe back pain from several collapsed vertebrae rather than a single one.

Why denosumab behaves this way#

Denosumab is a monoclonal antibody that binds RANKL, the signal osteoclasts need to mature and dissolve bone. Block that signal and resorption drops fast, density rises, and fracture risk falls. The distinctive part is how the effect disappears. Picture a bisphosphonate by contrast: it locks into the bone mineral and stays there for months to years, so its protection fades slowly, like a reservoir draining. Denosumab leaves no such reservoir. Once a scheduled dose is missed and the antibody clears, RANKL signaling switches back on and the osteoclast population that had been held down comes back, frequently overshooting its starting point.

The ECTS position statement in the Journal of Clinical Endocrinology and Metabolism (2021) lays out this sequence: bone turnover markers rise within a few months of a missed dose, climb past baseline, and the density gained on treatment is largely erased within about one to two years. Clinicians call this rebound. It is better understood as the predictable tail end of a reversible drug than as a conventional side effect.

Why timing and pattern change the clinical calculus#

Two features make rebound worth understanding when you start treatment, not only when you finish it. The first is that the danger is time-limited but front-loaded: it concentrates in the year or so after a dose lapses, which means a delayed or forgotten injection is not a harmless gap in your treatment but the opening of a specific window. The second is the multiple-fracture pattern, which raises the stakes of that single missed window, since several spinal fractures together bring far more pain and disability than one.

This is also why advice that fits other osteoporosis drugs does not carry over. A bisphosphonate can sometimes be paused as a planned drug holiday because its mineral-bound reserve keeps working in the background. Denosumab offers no reserve, so there is no genuine holiday available to you, only a handoff or a cliff.

What guidelines advise#

The ECTS position statement recommends reassessing after about five years of denosumab and, for anyone who does stop, giving a follow-on antiresorptive such as a bisphosphonate to soften the turnover rebound rather than discontinuing outright. Guidance summarized in the 2023 review suggests timing that follow-on treatment to roughly six months after the last denosumab injection, ahead of the rebound window. The best drug, timing, and duration remain debated, and the evidence for these transition strategies is thinner than the evidence for the rebound itself. What the recommendations agree on is one idea: choosing to stop denosumab is really choosing what will replace it. If you and your prescriber are discussing stopping, that is the question actually on the table.